A Randomized, Double-blind, Placebo-controlled, Multiple Dose-Ranging Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Solrikitug in Participants With Chronic Obstructive Pulmonary Disease (ZION)
Latest Information Update: 14 Aug 2026
At a glance
- Drugs Solrikitug (Primary)
- Indications Chronic obstructive pulmonary disease
- Focus Therapeutic Use
Most Recent Events
- 11 Aug 2026 Planned End Date changed from 31 Oct 2026 to 1 Feb 2027.
- 11 Aug 2026 Planned primary completion date changed from 30 Jun 2026 to 30 Sep 2026.
- 11 Aug 2026 Status changed from recruiting to active, no longer recruiting.